Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Non-Current Assets (2019 - 2026)

ADC Therapeutics has reported Non-Current Assets over the past 8 years, most recently at $14.7 million for Q1 2026.

  • Quarterly results put Non-Current Assets at $14.7 million for Q1 2026, up 1.22% from a year ago — trailing twelve months through Mar 2026 was $37.0 million (down 52.48% YoY), and the annual figure for FY2025 was $16.8 million, down 45.27%.
  • Non-Current Assets reached $14.7 million in Q1 2026 per ADCT's latest filing, down from $16.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $96.0 million in Q2 2022 and bottomed at $2.6 million in Q3 2025.
  • Median Non-Current Assets over the past 5 years was $17.8 million (2024), compared with a mean of $42.3 million.
  • The largest annual shift saw Non-Current Assets skyrocketed 66.17% in 2024 before it crashed 83.77% in 2025.
  • Over 5 years, Non-Current Assets stood at $11.6 million in 2022, then soared by 59.03% to $18.5 million in 2023, then surged by 66.17% to $30.7 million in 2024, then plummeted by 45.27% to $16.8 million in 2025, then decreased by 12.41% to $14.7 million in 2026.
  • Business Quant data shows Non-Current Assets for ADCT at $14.7 million in Q1 2026, $16.8 million in Q4 2025, and $2.6 million in Q3 2025.